SCHEMBL8286204

SCHEMBL8286204

CCOC(=O)c1ccc2c(c1)nc(N)n2Cc1nc(C)ccc1OCc1ccccc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CSF1R P07333 7/20 0.50
▸ HTT P42858 2/20 0.49
▸ HSD17B10 Q99714 1/20 0.49
▸ NPC1 O15118 2/20 0.48
▸ MEN1 O00255 2/20 0.48
▸ KMT2A Q03164 2/20 0.48
▸ RAB9A P51151 1/20 0.48
▸ MAPT P10636 5/20 0.47
▸ NPSR1 Q6W5P4 1/20 0.47
▸ ALDH1A1 P00352 3/20 0.45
▸ POLB P06746 2/20 0.45
▸ NLRP3 Q96P20 1/20 0.44
▸ SIRT2 Q8IXJ6 3/20 0.44
▸ SIRT1 Q96EB6 3/20 0.44
▸ RECQL P46063 1/20 0.44
▸ PDE2A O00408 1/20 0.43
▸ TSHR P16473 1/20 0.43
▸ KDM4E B2RXH2 1/20 0.41
▸ LMNA P02545 1/20 0.41
▸ GAA P10253 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12226819 0.93 CSF1R (0.50) CSF1RHTTHSD17B10NPC1MEN1
SCHEMBL12226886 0.86 MAPT (0.49) HTTHSD17B10NPC1MEN1KMT2A
SCHEMBL8286213 0.84 CSF1R (0.53) CSF1RHTTALDH1A1POLB
SCHEMBL8286215 0.83 CSF1R (0.57) CSF1RHTTALDH1A1POLB
SCHEMBL8284696 0.82 SIRT2 (0.48) NPC1MEN1KMT2ARAB9AMAPT
SCHEMBL8286225 0.82 CSF1R (0.53) CSF1RHTTALDH1A1POLB
SCHEMBL12226889 0.79 MEN1 (0.43) CSF1RNPC1MEN1KMT2ARAB9A
SCHEMBL8283857 0.78 CSF1R (0.57) CSF1RHTTALDH1A1POLB
SCHEMBL8284622 0.77 SIRT2 (0.50) HTTHSD17B10NPC1MEN1KMT2A
SCHEMBL8283854 0.76 CSF1R (0.53) CSF1RHTTALDH1A1POLBTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8044073-B2 Aminobenzimidazoles and benzimidazoles as inhibitors of respiratory syncytial virus replication TIBOTEC PHARMACEUTICALS (IE) 2011-10-25 — — US disclosed
US-8044073-B2 Aminobenzimidazoles and benzimidazoles as inhibitors of respiratory syncytial virus replication TIBOTEC PHARMACEUTICALS (IE) 2011-10-25 — — US disclosed
US-20070099924-A1 Aminobenzimidazoles and benzimidazoles as inhibitors of respiratory syncytial virus replication JANSSEN SCIENCES IRELAND UC (IE) 2007-05-03 — — US disclosed
US-20070099924-A1 Aminobenzimidazoles and benzimidazoles as inhibitors of respiratory syncytial virus replication JANSSEN SCIENCES IRELAND UC (IE) 2007-05-03 — — US disclosed
WO-2005058869-A1 AMINOBENZIMIDAZOLES AND BENZIMIDAZOLES AS INHIBITORS OF RESPIRATORY SYNCYTIAL VIRUS REPLICATION TIBOTEC PHARMACEUTICALS LTD. (IE) 2005-06-30 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070099924-A1 Aminobenzimidazoles and benzimidazoles as inhibitors of respiratory syncytial virus replication H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, H1-2, H1-4 CSF1R 4129/4885HTT 2862/4885HSD17B10 2027/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback